证券日报网讯1月5日，泓博医药（301230）在互动平台回答投资者提问时表示，截至2025年12月19日 (交易日)，公司的股东户数为14209户。 ...

Group 1 - The core viewpoint of the news is that Hongbo Pharmaceutical has shown significant financial performance with a notable increase in revenue and net profit for the period ending September 2025, alongside high financing activity [2][3] Group 2 - As of December 31, Hongbo Pharmaceutical's stock price increased by 1.29%, with a trading volume of 54.76 million yuan [1] - The financing buy-in amount on December 31 was 4.24 million yuan, while the financing repayment was 5.76 million yuan, resulting in a net financing buy of -1.52 million yuan [1] - The total financing and securities balance for Hongbo Pharmaceutical reached 215 million yuan, accounting for 5.15% of its market capitalization, indicating a high level of financing activity compared to the past year [1] Group 3 - For the period from January to September 2025, Hongbo Pharmaceutical achieved an operating income of 514 million yuan, representing a year-on-year growth of 31.43% [2] - The net profit attributable to the parent company was approximately 34.75 million yuan, reflecting a year-on-year increase of 127.96% [2] Group 4 - Since its A-share listing, Hongbo Pharmaceutical has distributed a total of 142 million yuan in dividends [3] - As of September 30, 2025, the top ten circulating shareholders included Changcheng Consumption Value Mixed A, holding 1.60 million shares, with no change in the number of shares held [3]

证券代码：301230 证券简称：泓博医药 公告编号：2025-067 上海泓博智源医药股份有限公司 股东询价转让结果报告书暨持股 5%以上股东 权益变动触及 5%整数倍的提示性公告 股东泓博智源（香港）医药技术有限公司、上海鼎蕴投资管理咨询合伙企业（有限 合伙）、蒋胜力、安荣昌保证向本公司提供的信息内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 1、本次权益变动主体为泓博智源（香港）医药技术有限公司（以下简称"出 让方"、"香港泓博"）及一致行动人上海鼎蕴投资管理咨询合伙企业（有限合 伙）（以下简称"上海鼎蕴"）、蒋胜力、安荣昌，合计持有上海泓博智源医药 股份有限公司（以下简称"泓博医药"或"公司"）5%以上股份。本次权益变动 方式为股份减少（询价转让），本次权益变动后，出让方及一致行动人拥有权益 的股份占公司总股本的比例由 44.94%下降至 39.94%，占剔除公司回购专用账户 股份后总股本的比例由 45.61%下降至 40.53%（以下简称"本次权益变动"）， 权益变动 ...

中信证券股份有限公司 关于上海泓博智源医药股份有限公司 股东向特定机构投资者询价转让股份的核查报告 深圳证券交易所： 中信证券股份有限公司（以下简称"中信证券"或"组织券商"）受委托担任泓博 智源（香港）医药技术有限公司（以下简称"出让方"）以向特定机构投资者询价转让 （以下简称"询价转让"）方式减持所持有的上海泓博智源医药股份有限公司（以下简 称"公司"或"泓博医药"）首次公开发行前已发行股份的组织券商。 经核查，中信证券就本次询价转让的股东、出让方是否符合《深圳证券交易所上市 公司自律监管指引第 16 号——创业板上市公司股东询价和配售方式转让股份（2025 年 修订）》（以下简称"《询价转让和配售指引》"）要求，本次询价转让的询价、转让 过程与结果是否公平、公正，是否符合《询价转让和配售指引》的规定作出如下报告说 明。 一、本次询价转让概况 （一）本次询价转让出让方 截至 2025 年 12 月 24 日，出让方所持公司首发前股份的数量及占公司总股本比例 情况如下： | 序号 | 股东名称 | 持股数量（股） | 占公司总股本比例 | | --- | --- | --- | --- | | 1 | 泓博 ...

上海泓博智源医药股份有限公司 简式权益变动报告书 信息披露义务人一：泓博智源（香港）医药技术有限公司 住所及通讯地址：Unit D, 16/F, One Capital Place, 18 Luard Road, Wan Chai, Hong Kong 信息披露义务人二：上海鼎蕴投资管理咨询合伙企业（有限合伙） 住所及通讯地址：上海市浦东新区龙东大道 6111 号 1 幢 C303 室 信息披露义务人三：安荣昌 股权变动性质：股份减少（询价转让） 签署日期：2025 年 12 月 31 日 1 上市公司名称：上海泓博智源医药股份有限公司 股票上市地点：深圳证券交易所创业板 股票简称：泓博医药 股票代码：301230 住所及通讯地址：辽宁省沈阳市 信息披露义务人四：蒋胜力 住所及通讯地址：上海市浦东新区 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办法》《公 开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》及相关法律、法 规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》《上市公司收 ...

Group 1 - Guangdong Construction signed an EPC contract worth 416 million yuan, with a total construction area of 99,595.6 square meters and a construction period of 640 calendar days [1] - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [2] - Jinbei Automotive signed a memorandum of understanding with E-Works to establish a research and development center for electric light commercial vehicles [3] Group 2 - Hongsheng Huayuan is expected to win approximately 569 million yuan in procurement projects from the State Grid, which represents about 5.61% of the company's projected revenue for 2024 [4] - Zhongding Co. plans to establish a joint venture for humanoid robot manufacturing with a registered capital of 50 million yuan [5] - Kede CNC's new factory in Shenyang is expected to achieve an annual production capacity of about 60 units [6] Group 3 - Hongbo Pharmaceutical's share transfer price is set at 25.27 yuan per share [7] - ST Jinglan plans to sign a letter of intent for the acquisition of Xinlian Environmental Technology Co., enhancing its core technology competitiveness [8][9] - Hato Co. announced the resignation of its general manager due to job relocation [10] Group 4 - Meibang Co. plans to apply for a new bank credit line of up to 160 million yuan [11] - Southern Media's general manager resigned due to job relocation [12] - Dalian Electric Porcelain's subsidiary is expected to win procurement projects from the State Grid worth approximately 70.7 million yuan [13] Group 5 - Sinopharm Modern's subsidiary received a drug registration certificate for a new medication [14] - ST Meigu plans to implement a capital reserve transfer to increase share capital, leading to a one-day stock suspension [15] - Ruisheng Intelligent confirmed a transaction of 152 million yuan for domestic computing equipment procurement [16] Group 6 - Jinguang Electric won three procurement packages from the State Grid, totaling 37.43 million yuan [17] - Guangju Energy increased its stake in Mawan Power to 14.42% by acquiring an 8% share for 680 million yuan [18][19] - ST Lingda announced a stock suspension due to capital reserve transfer related to its restructuring plan [20] Group 7 - Suli Co. plans to increase its investment in Suli Ningxia by 76.63 million yuan [21] - Dalian Shengya's subsidiary plans to reduce its registered capital by 32.37 million yuan [22] - Yinxin Technology received a cash dividend of 11.05 million yuan from its subsidiary [23] Group 8 - Haike New Source signed a three-year supply agreement for 270,000 tons of electrolyte materials [24] - Xinhua Medical received registration certificates for several medical devices [25] - Wantai Bio received a registration certificate for an HIV antibody testing kit [26] Group 9 - Beilu Pharmaceutical obtained a drug registration certificate for a new erectile dysfunction treatment [31] - Zhongwei Company is planning to issue shares to acquire assets, leading to a stock suspension [32] - Zhejiang Haideman plans to purchase land for strategic development, with a budget of up to 260 million yuan [33] Group 10 - Ningbo Ocean announced the resignation of its deputy general manager due to job adjustments [34] - Tongguang Cable is expected to win procurement projects from the State Grid worth over 139 million yuan [35]

泓博医药公告，根据2025年12月25日询价申购情况，初步确定的本次询价转让价格为25.27元/股。本次 询价转让不通过集中竞价交易或大宗交易方式进行，不属于通过二级市场减持。受让方通过询价转让受 让的股份，在受让后6个月内不得转让。 （文章来源：第一财经） ...

格隆汇12月25日丨泓博医药(301230.SZ)公布，经向机构投资者询价后，初步确定的转让价格为25.27元/ 股。本次询价转让拟转让股份已获全额认购，初步确定受让方为20家机构投资者，拟受让股份总数为 6,979,330股。 ...

泓博医药公告，2025年12月25日询价申购显示，本次股东询价转让初步定价25.27元/股，24家机构有效 认购1387.8万股，有效认购倍数1.99倍；拟转让697.93万股已全额认购，初步确定20家机构为受让方； 本次转让不通过集中竞价交易或大宗交易方式进行，受让方受让后6个月内不得转让。 ...

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 证券代码：301230 证券简称：泓博医药 公告编号：2025-066 上海泓博智源医药股份有限公司 股东询价转让定价情况提示性公告 股东泓博智源（香港）医药技术有限公司保证向上海泓博智源医药股份有限 公司提供的信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真 实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为25.27元/股。 （二）参与本次询价转让报价的机构投资者家数为24家，涵盖了基金管理公 司、证券公司、私募基金管理人、合格境外投资者等专业机构投资者。参与本次 询价转让报价的机构投资者合计有效认购股份数量为13,878,000股，对应的有效 认购倍数为1.99倍。 （三）本次询价转让拟转让股份已获全额认购，初步确定受让方为20家机构 投资者，拟受让股份总数为6,979,330股。 二、相关风险提示 （二）本次询价转让不涉及公司控制权变更，不会影响公司治理结构和持续 经营。 特此公告。 上海泓博智源医药股份有限公司 董事会 1 根据2025年12 ...